12 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 17 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 12, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Type II Diabetes Mellitus: new trials by email Literature Review of Type II Diabetes Mellitus trials Research Report on Type II Diabetes Mellitus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| cfMSC Therapy for Diabetes cfMSC therapy for diabetes - Type II Diabetes Mellitus | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency GL0034 - Type II Diabetes Mellitus | Phase 1 | Recruiting | Sun Pharmaceutical Industries Limited | 40 | 2026-02-25 | 2026-03-13 |
| A Clinical Trial to Evaluate the Food Effect of CKD-379 CKD-379 - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2024-11-05 | 2024-12-30 |
| A Clinical Trial to Evaluate the Food Effect of CKD-378 CKD-378, QD, PO - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2024-05-03 | 2024-07-08 |
| Study to Evaluate the Safety and Pharmacokinetics of CKD-379 CKD-379, D759+D745+D029+D150 - Type II Diabetes Mellitus | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 32 | 2023-06-02 | 2023-07-19 |
| Pharmacokinetics and Safety/Tolerability of CKD-379 CKD-379, D759+D745+D150 - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 32 | 2023-02-27 | 2023-05-11 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects CKD-371 - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 32 | 2022-10-21 | 2023-03-22 |
| Pharmacokinetics and Safety/Tolerability Profile of CKD-379 CKD-379 I, CKD-379 II, D759+D745+D150 - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2022-07-26 | 2022-10-18 |
| Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393 CKD-393 - Type II Diabetes Mellitus | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 28 | 2022-06-21 | 2022-11-30 |
| Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg D308 10mg Tab., CKD-380 10mg Tab. - Type II Diabetes Mellitus | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 34 | 2018-07-16 | 2018-07-26 |
| A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM Daily injection of KBP/placebo for up to 28 days - Type II Diabetes Mellitus | Phase 1 | Terminated | KeyBioscience AG | 25 | 2018-04-17 | 2020-09-03 |
| Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus Exenatide injection(Byetta), PB-119 injection - Type II Diabetes Mellitus | Phase 1 | Completed | PegBio Co., Ltd. | 36 | 2015-04-08 | 2017-02-23 |
| A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers HMS5552, Placebo - Type II Diabetes Mellitus | Phase 1 | Completed | Hua Medicine Limited | 60 | 2013-09-01 | 2017-11-20 |
| Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes CM3.1-AC100 - Type II Diabetes Mellitus | Phase 1 | Completed | CellMed AG, a subsidiary of BTG plc. | 16 | 2010-09-01 | 2010-12-06 |
| Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea AZD1656, Placebo - Type II Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 75 | 2009-10-01 | 2010-02-26 |
| Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM) AZD1656 - Type II Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 6 | 2009-07-01 | 2009-09-16 |
| Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes Resonator Device - Type II Diabetes Mellitus | Phase 1 | Completed | pico-tesla Magnetic Therapies, LLC | 60 | 2009-01-01 | 2010-12-15 |
Diabetes Mellitus, Type 2 (17) · Insulin Resistance (1)
Diabetes Mellitus (17) · Endocrine System Diseases (17) · Glucose Metabolism Disorders (17) · Metabolic Diseases (17) · Nutritional and Metabolic Diseases (17) · Hyperinsulinism (1)
AZD1656 (1) · Dorzagliatin (1)
Chong Kun Dang Pharmaceutical (8) · AstraZeneca (2) · CellMed AG, a subsidiary of BTG plc. (1) · Hua Medicine Limited (1) · KeyBioscience AG (1) · PegBio Co., Ltd. (1) · Shenzhen Geno-Immune Medical Institute (1) · Sun Pharmaceutical Industries Limited (1) · pico-tesla Magnetic Therapies, LLC (1)
South Korea (8) · United States (4) · China (3) · Germany (2)
Jaeseong Oh, M.D., Ph.D. (2) · Emeline Ramos, MD (1) · Hyewon Chung, M.D., Ph.D. (1) · Klas Malmberg, MD, PhD (1) · Klas Malmberg, MD, PhD, Prof., (1) · Marcus Dr. Marcus Hompesch, Dr (1) · Peter Geigle, Dr. med. (1) · Seol Ju Moon, M.D, Ph.D. (1) · Seunghoon Han, Professor (1) · Tim Heise, MD (1) · XueNing LI, MD (1) · Yuan Lv (1)